News >

Maintenance Rucaparib Improves PFS in Ovarian Cancer

Jason Harris
Published: Monday, Jun 19, 2017

Robert L. Coleman, MD

Robert L. Coleman, MD

Phase III data from the ARIEL3 trial showed that rucaparib (Rubraca) improved progression-free survival (PFS) versus placebo as a maintenance treatment for women with platinum-sensitive, high-grade ovarian, fallopian tube, or primary peritoneal cancer.
... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Publication Bottom Border
Border Publication